Abstract：Objective: To investigate the effects of miR36913pregulated target genes E2F3 and PRDM1 on the proliferation, migration and invasion of prostate cancer DU145 cell line. Methods: miR36913p mimic with various concentrations was transfected into DU145 cell line, RTPCR and Western blotting were used to detect the expression level of E2F3, PRDM1 mRNA and protein. The small interfering RNA scrambled siRNA, E2F3 siRNA and PRDM1 siRNA were transfected into DU145 cells. The expression levels of E2F3, PRDM1 mRNA were detected by RTPCR and MTT, Transwell and scratch tests were used to detect the proliferation, migration and invasion of DU145 cell line. Results: The expression of E2F3(P<0.01) and PRDM1(P<0.05) mRNA decreased with the increase of miR36913p mimic transfection concentration in DU145 cell line, the expression level of both two protein were decreased (P<0.01). Compared with the negative control group, the expression of E2F3 and PRDM1 in DU145 cell lines transfected with E2F3 siRNA and PRDM1 siRNA were significantly decreased (E2F3: t=31, P<0.01; PRDM1: t=10.44, P<0.01). The proliferation, migration and invasion of DU145 cells transfected with E2F3 siRNA, were significantly decreased (all P<0.01). The proliferation, invasion of DU145 cells transfected with PRDM1 siRNA were significantly decreased(all P<0.01), but the migration ability was not changed(P>0.05). Conclusion: The expression of miR36913p is low in DU145 cells, promoting the biological characteristics of cells by targeting E2F3 and PRDM1.
［1］Filippou P, Ferguson JE 3rd, Nielsen ME. Epidemiology of prostate and testicular cancer\[J\]. Semin Intervent Radiol, 2016, 33(3):182-185.［2］Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014\[J\]. CA Cancer J Clin, 2014, 64(1):9-29.［3］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015\[J\]. CA Cancer J Clin, 2015, 65(1):5-29.［4］Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation\[J\]. Cell, 2011, 144(5):646-674.［5］Ambros V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing\[J\]. Cell, 2003, 113(6):673-676.［6］Yates LA, Norbury CJ, Gilbert RJC. The Long and Short of MicroRNA\[J\]. Cell, 2013, 153(3):516-519.［7］Orellana EA, Kasinski AL. MicroRNAs in cancer: A historical perspective on the path from discovery to therapy\[J\]. Cancers (Basel), 2015, 7(3):1388-1405.［8］Lagan A. Computational prediction of microRNA targets\[J\]. Adv Exp Med Biol,2015, 887:231-252.［9］Lewis BP, Shih IH, JonesRhoades MW, et al. Prediction of mammalian microRNA targets\[J\]. Cell, 2003, 115(7):787-798.［10］John B, Enright AJ,Aravin A,et al.Human MicroRNA targets\[J\].PLoS Biol,2004,2(11): e363.［11］Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions\[J\]. Nat Genet, 2005, 37(5):495-500.［12］Kiriakidou M, Nelson PT, Kouranov A, et al. A combined computationalexperimental approach predicts human microRNA targets\[J\]. Genes Dev, 2004, 18(10):1165-1178.［13］Hohenauer T, Moore AW. The Prdm family: expanding roles in stem cells and development\[J\]. Development, 2012, 139(13):2267-2282.［14］Boi M, Zucca E, Inghirami G, et al. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas\[J\]. Leuk Lymphoma, 2015, 56(5):1223-1228.［15］Xiao F, Zhang W, Chen L, et al. MicroRNA503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma\[J\]. J Transl Med, 2013, 11:195.［16］Ohtsuka M, Ling H, Doki Y, et al. MicroRNA processing and human cancer\[J\]. J Clin Med, 2015, 4(8):1651-1667.［17］Li F,Piao M,Piao Y, et al. A new direction of cancer classification: positive effect of lowranking MicroRNAs\[J\]. Osong Public Health Res Perspect, 2014, 5(5):279-285.［18］Di Leva G, Croce CM. miRNA profiling of cancer\[J\]. Curr Opin Genet Dev, 2013, 23(1):3-11.［19］Bartel DP.MicroRNAs:Target recognition and regulatory functions\[J\].Cell,2009,136(2): 215-233.［20］Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control\[J\]. Nat Rev Cancer, 2009, 9(11):785-797.［21］Kauer M, Ban J, Kofler R, et al. A Molecular function map of ewing′s sarcoma\[J\]. PLoS One, 2009, 4(4):e5415.［22］Yu Z, Sato S, Trackman PC, et al. Blimp1 activation by AP1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide\[J\]. PLoS One, 2012, 7(3):e33287.
2018, Vol. 28 
